Heterogeneity of pathogenesis in multiple sclerosis

Implications for promotion of remyelination

M. M P Soldan, Moses Rodriguez

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Enhancing myelin repair remains an important therapeutic goal in primary demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis (MS). The emerging heterogeneity of pathology within MS lesions, and differential oligodendrocyte survival in particular, suggests that therapeutic strategies may need to be tailored to an individual patient's requirements. A number of therapeutic strategies have been proposed to enhance myelin repair in the CNS: cell transplantation, growth factor therapy, and antibody therapy, but each proposed therapy has different implications with respect to pathogenetic mechanisms of demyelination. Of these, antibody therapy is the most amenable to immediate application in patients - but a combination of therapeutic approaches may be required in practice.

Original languageEnglish (US)
JournalJournal of Infectious Diseases
Volume186
Issue numberSUPPL. 2
DOIs
StatePublished - Dec 1 2002

Fingerprint

Multiple Sclerosis
Demyelinating Diseases
Therapeutics
Myelin Sheath
Central Nervous System
Antibodies
Cell Transplantation
Oligodendroglia
Intercellular Signaling Peptides and Proteins
Pathology

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Heterogeneity of pathogenesis in multiple sclerosis : Implications for promotion of remyelination. / Soldan, M. M P; Rodriguez, Moses.

In: Journal of Infectious Diseases, Vol. 186, No. SUPPL. 2, 01.12.2002.

Research output: Contribution to journalArticle

@article{eb69930274ae4102b73a09f080973704,
title = "Heterogeneity of pathogenesis in multiple sclerosis: Implications for promotion of remyelination",
abstract = "Enhancing myelin repair remains an important therapeutic goal in primary demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis (MS). The emerging heterogeneity of pathology within MS lesions, and differential oligodendrocyte survival in particular, suggests that therapeutic strategies may need to be tailored to an individual patient's requirements. A number of therapeutic strategies have been proposed to enhance myelin repair in the CNS: cell transplantation, growth factor therapy, and antibody therapy, but each proposed therapy has different implications with respect to pathogenetic mechanisms of demyelination. Of these, antibody therapy is the most amenable to immediate application in patients - but a combination of therapeutic approaches may be required in practice.",
author = "Soldan, {M. M P} and Moses Rodriguez",
year = "2002",
month = "12",
day = "1",
doi = "10.1086/344283",
language = "English (US)",
volume = "186",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Heterogeneity of pathogenesis in multiple sclerosis

T2 - Implications for promotion of remyelination

AU - Soldan, M. M P

AU - Rodriguez, Moses

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Enhancing myelin repair remains an important therapeutic goal in primary demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis (MS). The emerging heterogeneity of pathology within MS lesions, and differential oligodendrocyte survival in particular, suggests that therapeutic strategies may need to be tailored to an individual patient's requirements. A number of therapeutic strategies have been proposed to enhance myelin repair in the CNS: cell transplantation, growth factor therapy, and antibody therapy, but each proposed therapy has different implications with respect to pathogenetic mechanisms of demyelination. Of these, antibody therapy is the most amenable to immediate application in patients - but a combination of therapeutic approaches may be required in practice.

AB - Enhancing myelin repair remains an important therapeutic goal in primary demyelinating diseases of the central nervous system (CNS) such as multiple sclerosis (MS). The emerging heterogeneity of pathology within MS lesions, and differential oligodendrocyte survival in particular, suggests that therapeutic strategies may need to be tailored to an individual patient's requirements. A number of therapeutic strategies have been proposed to enhance myelin repair in the CNS: cell transplantation, growth factor therapy, and antibody therapy, but each proposed therapy has different implications with respect to pathogenetic mechanisms of demyelination. Of these, antibody therapy is the most amenable to immediate application in patients - but a combination of therapeutic approaches may be required in practice.

UR - http://www.scopus.com/inward/record.url?scp=0036891085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036891085&partnerID=8YFLogxK

U2 - 10.1086/344283

DO - 10.1086/344283

M3 - Article

VL - 186

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - SUPPL. 2

ER -